1. |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版). 中国癌症杂志, 2021, 31(10): 954-1040.
|
2. |
Vici P, Pizzuti L, Natoli C, et al. Triple positive breast cancer: a distinct subtype? Cancer Treat Rev, 2015, 41(2): 69-76.
|
3. |
Zeng J, Edelweiss M, Ross DS, et al. Triple-positive breast carcinoma: histopathologic features and response to neoadjuvant chemotherapy. Arch Pathol Lab Med, 2021, 145(6): 728-735.
|
4. |
Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol, 2020, 9(3): 32. doi: 10.21037/cco-20-123.
|
5. |
Arpino G, Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev, 2008, 29(2): 217-233.
|
6. |
Giuliano AE, Ballman KV, Mccall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA, 2017, 318(10): 918-926.
|
7. |
Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast, 2003, 12(5): 320-327.
|
8. |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteriain solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2): 228-227.
|
9. |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [published correction appears in Lancet. 2019 Mar 9; 393(10175): 986]. Lancet, 2014, 384(9938): 164-172.
|
10. |
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 2008, 26(5): 778-785.
|
11. |
Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med, 2011, 135(1): 55-62.
|
12. |
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005, 353(16): 1673-1684.
|
13. |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010, 375(9712): 377-384.
|
14. |
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17(6): 791-800.
|
15. |
Thangarajah F, Enninga I, Malter W, et al. A retrospective analysis of Ki-67 index and its prognostic significance in over 800 primary breast cancer cases. Anticancer Res, 2017, 37(4): 1957-1964.
|
16. |
Chen X, He C, Han D, et al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Future Oncol, 2017, 13(9): 843-857.
|
17. |
刘润奇, 叶建森, 徐天鸣, 等. 乳腺癌Ki-67和CyclinD1在预测及评估新辅助化疗疗效中的价值. 西部医学, 2022, 34(5): 753-756, 760.
|
18. |
Aldawsari HM, Gorain B, Alhakamy NA, et al. Role of therapeutic agents on repolarisation of tumour-associated macrophage to halt lung cancer progression. J Drug Target, 2020, 28(2): 166-175.
|
19. |
袁茂林, 韩琼, 吴斌. 外周血淋巴细胞和单核细胞比值与乳腺癌新辅助化疗疗效关联性. 中华肿瘤防治杂志, 2020, 27(4): 283-287.
|
20. |
钱贝, 辛玥, 史薇, 等. 乳腺癌新辅助化疗疗效影响因素研究及预测模型构建. 华中科技大学学报(医学版), 2022, 51(1): 72-77.
|
21. |
Kurozumi S, Inoue K, Takei H, et al. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer, 2015, 15: 622. doi: 10.1186/s12885-015-1641-y.
|
22. |
Thanopoulou E, Khader L, Caira M, et al. Therapeutic strategies for the management of hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer: a review of the current literature. Cancers (Basel), 2020, 12(11): 3317. doi: 10.3390/cancers12113317.
|
23. |
Koboldt D, Fulton R, Mclellan M, et al. Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490(7418): 61-70.
|
24. |
Cheang Mcu, Prat A, Fan C, et al. S5-2: PAM50 HER2-enriched subtype enriches for tumor response to neoadjuvant anthracyclines/taxane and trastuzumab/taxane containing regimens in HER2-positive breast cancer. Cancer Res, 2012, 71 (24 Supplement): S5-2. doi: 10.1158/0008-5472.SABCS11-S5-2.
|
25. |
Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst, 2004, 96(12): 926-935.
|
26. |
Stoica A, Saceda M, Doraiswamy VL, et al. Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. J Endocrinol, 2000, 165(2): 371-378.
|
27. |
Vici P, Pizzuti L, Sperduti I, et al. “Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. Oncotarget, 2016, 7(14): 17932-17944.
|
28. |
de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol, 2014, 15(10): 1137-1146.
|